This slide deck on the European Union (EU) drug approval and reimbursement policy was presented by Mait Raava, Estonian Myeloma Society, during the Global Myeloma Action Network (GMAN) meeting held in Copenhagen on June 11, 2016.

This presentation discusses the lack of a standardized cost-benefit formula across the EU, the impact of this on multiple myeloma patients, and the GMAN's proposed solution and vision for the future.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.